TP53 and carcinoma: The KRAS mutation frequency was again lower in adenoma than in carcinoma samples (32.4% vs. 45.5%, 0.31), while the TP53 mutations frequency was the lower in adenomas and the highest in carcinoma samples (12.2% vs. 18.2%, p = 0.27).